WRN

Nimbus Therapeutics Appoints Anita Scheuber, M.D., Ph.D., as Senior Vice President, Therapeutic Area Head, Oncology

Retrieved on: 
tisdag, maj 7, 2024
Biometrics, Health, Pharmaceutical, Clinical Trials, Oncology, University, Trillium, Nimbus, Drug, Trial of the century, Growth, WRN, Pfizer, GSK, Patient, University Hospital of Zürich, Harvard Medical School, Teaching hospital, HPK1, Therapy, Werner syndrome helicase, Biotechnology, Pharmaceutical industry

Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced the appointment of Anita Scheuber, M.D., Ph.D., as Senior Vice President, Therapeutic Area Head, Oncology.

Key Points: 
  • Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced the appointment of Anita Scheuber, M.D., Ph.D., as Senior Vice President, Therapeutic Area Head, Oncology.
  • “We are delighted to welcome Anita to the executive team as we enter a new stage of growth at Nimbus with plans to further expand our focus in oncology,” said Nathalie Franchimont, M.D., Ph.D, Chief Medical Officer at Nimbus.
  • Most recently, she provided strategic consulting to biotechnology companies, developing clinical development strategies for multiple early-stage oncology assets.
  • Previously, she served as Vice President and Head of Clinical Development, Oncology at Trillium Therapeutics (acquired by Pfizer in 2021).

Western Copper and Gold Announces Upsize in Bought Deal Public Offering to $40 Million

Retrieved on: 
tisdag, april 16, 2024
Sale, Indian stock exchange, Prospectus, Offering, News, Suite, TSX, Exchange, Gold Corporation, Form, Toronto Stock Exchange, WRN, EDGAR, Gold, Register, Security (finance)

The Prospectus and the Registration Statement are subject to completion and amendment.

Key Points: 
  • The Prospectus and the Registration Statement are subject to completion and amendment.
  • Such documents contain important information about the Offering.
  • The Registration Statement relating to the Common Shares has been filed with the United States Securities and Exchange Commission but has not yet become effective.
  • The Offering is expected to close on or about April 30, 2024 and is subject to the Company receiving all necessary regulatory approvals, including that of the Toronto Stock Exchange and the NYSE American LLC.

Western Copper and Gold Announces $25 Million Bought Deal Public Offering

Retrieved on: 
måndag, april 15, 2024
Sale, Indian stock exchange, Prospectus, Offering, News, Suite, TSX, Exchange, Gold Corporation, Form, Toronto Stock Exchange, WRN, EDGAR, Gold, Register, Security (finance)

The Prospectus and the Registration Statement are subject to completion and amendment.

Key Points: 
  • The Prospectus and the Registration Statement are subject to completion and amendment.
  • Such documents contain important information about the Offering.
  • The Registration Statement relating to the Common Shares has been filed with the United States Securities and Exchange Commission but has not yet become effective.
  • The Offering is expected to close on or about April 30, 2024 and is subject to the Company receiving all necessary regulatory approvals, including that of the Toronto Stock Exchange and the NYSE American LLC.

Vividion Therapeutics and Roche Jointly Publish Landmark Nature Paper on Clinical-Stage Covalent Allosteric Inhibitor of Werner Helicase (WRN)

Retrieved on: 
torsdag, april 25, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Molecule, MSI, Werner syndrome, Roche, DNA, WRN, Therapy, DSM-IV codes, Microsatellite instability, Drug development, Drug discovery, Cancer, Development, Head, Pharmaceutical industry

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced a landmark publication in Nature.

Key Points: 
  • Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced a landmark publication in Nature.
  • The publication, “Chemoproteomic Discovery of a Covalent Allosteric Inhibitor of WRN Helicase,” by Kristen Baltgalvis et al, published jointly with our partner Roche, speaks to the chemical proteomic-enabled discovery of a clinical-stage, covalent allosteric inhibitor of Werner helicase (WRN), VVD-133214 (RO7589831), and further confirms Vividion’s approach to discovering and developing novel therapeutics.
  • “Vividion discovered covalent ligands targeting a novel allosteric pocket on WRN, a well- known but challenging therapeutic target in drug development.
  • The WRN molecule was identified under the collaboration agreement entered between Vividion and Roche in 2020.

Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Retrieved on: 
onsdag, april 10, 2024
PV, MSI, PIM, MTAP, RecQ helicase, Cell, MF, Christian democracy, Safety, PARP, Pancreatic serous cystadenoma, Polycythemia vera, Colorectal cancer, PLN, Polycythemia, MPN, CRC, Collection, Research, MTA, Haematopoiesis, Three-sector model, WBC, WRN, Therapy, Ruxolitinib, PDC, Chemical substance, Splenomegaly, Neoplasm, Intellectual property, Standard of care, AACR, Drug discovery, PRMT5, Vaccine

RVU120 shows efficacy both as a monotherapy and synergistically in combination with ruxolitinib in preclinical models of myeloproliferative neoplasms, including myelofibrosis and polycythemia vera.

Key Points: 
  • RVU120 shows efficacy both as a monotherapy and synergistically in combination with ruxolitinib in preclinical models of myeloproliferative neoplasms, including myelofibrosis and polycythemia vera.
  • KRAKOW, Poland, April 10, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, presents preclinical data from its synthetic lethality pipeline, RVU120, and MEN1703 (SEL24) at the 2024 AACR Annual Meeting, April 5-10 in San Diego, California.
  • "We are excited to present our latest advancements in oncology therapeutics at the AACR Annual Meeting this year.
  • Strong preclinical data from our two lead synthetic lethality programs – PRMT5 and WRN – are encouraging as we make progress toward the identification of competitive clinical candidates," said Krzysztof Brzózka, Ph.D., Chief Scientific Officer of Ryvu Therapeutics.

CENIC Recognizes Pacific Northwest Gigapop for Efforts that Expand Research and Education Networking in North America and Beyond

Retrieved on: 
måndag, mars 11, 2024
Technology, Research, Telecommunications, Networks, Internet, University, Primary, Secondary, Science, Education, AMPATH, Physics, Astronomy, Internet2, Organization, Earth, Biomedical engineering, Computation, WRN, Partnership, Genetics, University of Hawaiʻi, Artificial intelligence, Biology, WIX, Large Hadron Collider, Empowerment, Radio, Telescope, Geography, Internet exchange point, Starlight, Machine learning, CENIC, Pacific Rim, Engineering, Virtual reality, Drug

The CENIC Innovations in Networking Awards recognize exemplary people, projects, and organizations that leverage high-bandwidth networking.

Key Points: 
  • The CENIC Innovations in Networking Awards recognize exemplary people, projects, and organizations that leverage high-bandwidth networking.
  • The PNWGP is renowned for its expertise in connecting diverse institutions, fostering collaborative environments, and driving technological innovation.
  • Through their work, PNWGP has effectively bridged geographic and institutional boundaries, enabling researchers and educators to access and share vast resources seamlessly.
  • It provides advanced, robust high-speed networking for research, education, and related uses leveraging Internet2’s optical infrastructure.

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Retrieved on: 
onsdag, mars 6, 2024
WBC, WRN, Lung cancer, RNA, Malignancy, Microsatellite instability, Proteome, Intellectual property, MMR, MPN, Glioblastoma, Neoplasm, Splenomegaly, DMPK, Phosphorylation, HDAC, STAT5, RNA-Seq, WES, Standard of care, Therapy, RecQ helicase, Phenotype, Ruxolitinib, DNA, DNA repair, Pancreatic serous cystadenoma, CDKN2A, Cancer, CRC, PIM, Arginine, MTA, Abstract, PDC, MTAP, Colorectal cancer, CRISPR, PV, MF, MSI-H, Cell, JAK, DNA mismatch repair, Medicine, Patient, Gene, PRMT5, Haematopoiesis, Mesothelioma, Pharmaceutical industry

Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.

Key Points: 
  • Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.
  • "We are excited to present our latest preclinical data at the AACR Annual Meeting, showcasing our significant progress in advancing novel small molecule therapies for oncology.
  • This year, we will present data from our most advanced preclinical project on MTA-cooperative PRMT5 inhibitors, the lead program within Ryvu's synthetic lethality pipeline.
  • Ryvu has developed potentially best-in-class MTA-cooperative PRMT5 inhibitors showing favorable drug-like properties and effective PRMT5 inhibition dependent on MTA binding.

Eikon Therapeutics to Provide Corporate Updates at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
måndag, januari 8, 2024
Research, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Patient, TLR 7, Conference, Protein, Drug discovery, Food, PARP1, WRN, FDA, TLR, DNA, Therapy, Cancer, Cellular, Eikon, PARP, Toxicity, Safety, Pharmaceutical industry

“Eikon has made enormous progress in the development of advanced imaging tools that aid the discovery of important new therapeutics.

Key Points: 
  • “Eikon has made enormous progress in the development of advanced imaging tools that aid the discovery of important new therapeutics.
  • This program is led by Eikon with its collaboration partner, Impact Therapeutics, which is responsible for trial oversight in greater China.
  • Eikon Systems Business Unit Established: Eikon has developed a suite of instruments that permits detailed, automated characterization of protein motion in living cells.
  • An archived recording of Eikon’s presentation at the J.P. Morgan Healthcare Conference can be accessed at: www.EikonTx.com/#news .

Nimbus Therapeutics Announces Expansion of Its Immunology Drug Discovery Pipeline

Retrieved on: 
fredag, januari 5, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Biology, Conference, Family, Partnership, Drug discovery, Metabolism, WRN, IND, Drug design, Werner syndrome helicase, Pain scale, MBA, Therapy, Eli Lilly and Company, HPK1, DSM-IV codes, AMPK, Investment, Patient, TYK2, Pharmaceutical industry

Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, announced the advancement and expansion of its pipeline with the addition of discovery programs targeting innate immunity pathways.

Key Points: 
  • Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, announced the advancement and expansion of its pipeline with the addition of discovery programs targeting innate immunity pathways.
  • "Building on the success of our TYK2 program, we are broadening our drug discovery engine to unlock new difficult-to-drug targets with compelling biology,” said Peter Tummino, Ph.D., Chief Scientific Officer of Nimbus.
  • “SIK and cGAS are critical targets in highly prevalent diseases that are well suited to Nimbus’ structure-based drug design approach.
  • Nimbus continues to expand its platform capabilities with ongoing investments in cutting-edge technology for drug discovery.

Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
onsdag, november 29, 2023
Phase, Conference, AACR, WRN, IDH, MTA, Medulloblastoma, Sarcoma, Research, American Society of Hematology, Phases of clinical research, Society, Therapy, MDS, Pharmacokinetics, Lymphoma, Ruxolitinib, ASH, BioNTech, Common, Incentive program, Syndrome, MEK, Exelixis, Patient, AML, PRMT5, Principal investigator, Pharmaceutical industry

Ryvu’s PRMT5 program and synthetic lethality platform were highlighted with preclinical data recently presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

Key Points: 
  • Ryvu’s PRMT5 program and synthetic lethality platform were highlighted with preclinical data recently presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
  • KRAKOW, Poland, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today reported financial results for the third quarter of 2023 and provided a corporate update.
  • “The third quarter and the last months of 2023 proved to be an exceptionally productive period for our company,” said Pawel Przewięźlikowski, CEO of Ryvu Therapeutics.
  • Cash Position – On November 24, 2023, Ryvu Therapeutics held $64.5M in cash, cash equivalents, and bonds, compared to $23.2M at the end of 2022.